Figure 1


the spring 2015 DATIA focus. The current panel contains metabolites for 28 compounds and includes the most recently released compounds and updates through December 2015. To ensure effectiveness, the testing


cutoffs for each of these compound metabolites must be as low as possible based on available technology for confirmation and the availability of a second laboratory for reconfirmation of a Bottle B.


Results The following graphs reflect 4.5 years of testing and 200,000 workplace drug testing specimens performed by Clinical Reference Laboratory, Inc. Figure 1 contains a pie chart


Figure 2


summarizing the reason for test by category for calendar years 2011–2015. Over this 4 year period, the percentage of testing by category has remained relatively constant with Random and Pre- Employment combining for 52% of the total tests. Twenty-three percent of the testing was conducted under the testing category “Not-Specified” or “Other.” There were no attempts to contact these collection sites or employers for additional information. The next largest categories were “Reasonable Cause” (12%),”Post-Accident” (8%), “Follow- up” (4%), and “Return to Duty” (1%). Figure 2 “Positive Samples by Analyte 2015” graph illustrates the positive percentages for each of the primary synthetic cannabinoids tested. This graph is comprised of 2015 testing data only as earlier years have been previously published.(1,6)


The four most commonly


found synthetics, UR-144, AB-PINACA, 5-F-PB, and PB-22 collectively account for approximately 90% of all positives. The remaining synthetic compounds account for the final 10% of positive samples. Interestingly, the original synthetic compounds JWH-018 and


30 datia focus Spring 2016


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80